Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one. The approval extends the use of Dupixent ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Sanofi’s commitment to sustainability has been recognized globally, with TIME ranking it as the world’s 10th most sustainable company across all industries and #1 in pharma and biotech. This accolade ...

Sanofi’s U.S.-listed shares plunged more than 6% in premarket trading by 08:03 GMT, while Regeneron fell over 8%. In one study involving former smokers with uncontrolled chronic obstructive pulmonary ...

Sanofi’s asthma drug Dupixent met all targets in a trial to treat “smoker’s lung,” potentially adding billions to the French drugmaker’s growth prospects, but also underscoring a heavy reliance on its ...

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Regeneron and Sanofi have collaborated on Dupixent since 2007. Credit: The Washington Post via Getty Images. ·Pharmaceutical Technology·The Washington Post via Getty Images. Jenna Philpott Tue ...

Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a ...